Feasibility of Molecularly Targeted Therapy for Tooth Regeneration - New Trends in Tissue Engineering and Regenerative Medicine - page 63

6. Conclusion
We have a chance to access the formation of the third dentition in the mouth, because the timing
of the appearance of the third dentition seems to be after birth. The identification of mutations
in RUNX2 causing an isolated dental phenotype in CCD and supernumerary tooth formation
in the mouse model clearly demonstrated that it was possible to induce de novo tooth formation
by the in situ inhibition or activation of a single candidate molecule. These results support the
idea that the de novo inhbition or activation of candidate molecules such as RUNX2 or USAG-1
might be used to stimulate the third dentition in order to induce new tooth formation in the
mouse (Figure 4). Molecularly targeted therapy seems to be a suitable approach in tooth
regeneration by stimulation of the third dentition.
Acknowledgements
This work was supported by Grant-in-Aid for Scientific Research(C):22592213 and 25463081
and A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven
R&D) FS stage: AS231Z01061G and AS242Z02645Q.
Author details
Katsu Takahashi, Honoka Kiso, Kazuyuki Saito, Yumiko Togo, Hiroko Tsukamoto,
Boyen Huang and Kazuhisa Bessho
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto
University, Japan
References
[1] Aberg T, Cavender A, Gaikwad JS, Bronckers AL, Wang X, Waltimo-Sirén J, Thesleff
I, D'Souza RN. Phenotypic changes in dentition of Runx2 homozygote-null mutant
mice. J Histochem Cytochem 2004;52(1):131-139.
[2] Chimenos-Küstner E, Pascual M, Blanco I, Finestres F. Hereditary familial polyposis
and Gardner's syndrome: contribution of the odonto-stomatology examination in its
diagnosis and a case description. Med Oral Patol Oral Cir Bucal 2005;10(5):402-409.
[3] Edwards PC, Mason JM. Gene-enhanced tissue engineering for dental hard tissue re‐
generation: (1) overview and practical considerations. Head Face Med 2006;2:12.
[4] Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas. Biologics. 2014;8:91-105.